Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging, repetitive chewing, continuous blinking of the eyes, tongue thrusting, and others. 

The global Tardive Dyskinesia (TD) Therapy market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Tardive Dyskinesia (TD) Therapy volume and value at global level, regional level and company level. From a global perspective, this report represents overall Tardive Dyskinesia (TD) Therapy market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Tardive Dyskinesia (TD) Therapy in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Tardive Dyskinesia (TD) Therapy manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Teva Pharma
Biogen
Johnson & Johnson
GlaxoSmithKline
Neurocrine Biosciences
Pfizer
Novartis
Sanofi
AstraZeneca
Bayer AG

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Valbenazine
Amantadine
Tetrabenazine
Clonazepam
Others

Segment by Application
Hospitals
Clinics
Others